Scarica l'app Stockscreener
18.49
28.94%
4.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Clears Existing Data For Sonelokimab BLA In Hidradenitis Suppurativa - simplywall.st
MoonLake Options Trading: A Deep Dive into Market Sentiment - Benzinga
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations - Stocktwits
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation - FinancialContent
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug - Citeline News & Insights
MoonLake price target raised to $32 from $26 at H.C. Wainwright - TipRanks
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission (NASDAQ:MLTX) - Seeking Alpha
MLTX Analyst Rating: HC Wainwright & Co. Raises Price Target to $32.00 | MLTX Stock News - GuruFocus
Moonlake Immunotherapeutics stock upgraded to Buy at BTIG on FDA feedback - Investing.com
Will MoonLake's Clinical Milestones Send Investors Over The Moon? - RTTNews
Will MoonLake Immunotherapeutics stock benefit from AI adoptionJuly 2025 Update & High Conviction Trade Alerts - ulpravda.ru
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (MLTX) Is Up 20.0% After FDA Clears Existing SLK Data For HS BLA Path - Yahoo Finance
What margin trends mean for MoonLake Immunotherapeutics stockQuarterly Trade Review & High Conviction Investment Ideas - ulpravda.ru
Will MoonLake Immunotherapeutics stock reach all time highs in 2025CEO Change & Growth Focused Entry Reports - ulpravda.ru
Will MoonLake Immunotherapeutics stock benefit from sector rotationWeekly Gains Summary & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Biopharma bites: A flurry of financings headlined by Diagonal, plus updates from Servier, MoonLake - FirstWord
MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials - TechStock²
Will MoonLake Immunotherapeutics stock rally after Fed decisionsMarket Sentiment Report & Consistent Profit Trading Strategies - ulpravda.ru
Why MoonLake Immunotherapeutics stock could rally in 20252025 Top Gainers & Safe Investment Capital Preservation Plans - ulpravda.ru
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating - TipRanks
Biotech Soars 27% On FDA Deal For Beleaguered Skin Drug - Investor's Business Daily
MoonLake soars 45% after FDA clears path for key skin drug | Tap to know more | Inshorts - Inshorts
MLTX Surge: Will The Momentum Last? - StocksToTrade
What is the fair value of MoonLake Immunotherapeutics stock nowMarket Growth Review & Technical Entry and Exit Tips - ulpravda.ru
MoonLake States FDA Might Permit Skin Medication Submission Without Additional Studies, Shares Surge - Bitget
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars - Benzinga
MoonLake revives FDA push; Biotech trio to debut in Hong Kong - Endpoints News
De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026 - TipRanks
Can MoonLake Immunotherapeutics stock hit record highs again2025 Earnings Impact & Risk Controlled Swing Trade Alerts - ulpravda.ru
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $34 - 富途牛牛
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street - Investing.com South Africa
MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating - TipRanks
MoonLake Immunotherapeutics Shares Rise on FDA Alignment to File Application Without New Trials - MarketScreener
MoonLake provides update following positive feedback from U.S. FDA for SLK - TipRanks
Clear Street Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $45 - 富途牛牛
MLTX Stocks: Is the Price Right? - timothysykes.com
Why Did MLTX Stock Jump 45% In Pre-Market Today? - Stocktwits
MoonLake Immunotherapeutics price target raised to $45 from $12 at Clear Street - TipRanks
MoonLake Advances Sonelokimab After Positive FDA Feedback - TipRanks
Moonlake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. Fda - MarketScreener
FDA confirms MoonLake’s path to HS drug approval without additional trials - Investing.com
FDA confirms MoonLake’s path to HS drug approval without additional trials By Investing.com - Investing.com South Africa
MoonLake lead drug needs no additional trials (MLTX:NASDAQ) - Seeking Alpha
MoonLake stock soars after FDA feedback on HS treatment path By Investing.com - Investing.com South Africa
MoonLake stock soars after FDA feedback on HS treatment path - Investing.com
MoonLake Immunotherapeutics Announces Positive FDA Feedback on SLK - TradingView — Track All Markets
MoonLake Immunotherapeutics Announces Positive Outcome from - GlobeNewswire
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG - TipRanks
Will MoonLake Immunotherapeutics stock gain from strong economy2026 world cup usa national team quarterfinals playmakers low block defense odds analysis preview - ulpravda.ru
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.3%Time to Sell? - MarketBeat
(MLTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a 6.66% Potential Upside in Biotechnology - DirectorsTalk Interviews
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Hold" by Brokerages - MarketBeat
H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT - MSN
Responsive Playbooks and the MLTX Inflection - Stock Traders Daily
Trend Report: Will MoonLake Immunotherapeutics stock gain from strong economyWeekly Trade Analysis & Risk Managed Trade Strategies - Улправда
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):